{"meshTags":["Cell Line, Tumor","DNA Mutational Analysis","Drug Screening Assays, Antitumor","GTP Phosphohydrolases","Humans","Melanoma","Membrane Proteins","Mutation","Neurofibromin 1","Proto-Oncogene Proteins B-raf","Pyridones","Pyrimidinones"],"meshMinor":["Cell Line, Tumor","DNA Mutational Analysis","Drug Screening Assays, Antitumor","GTP Phosphohydrolases","Humans","Melanoma","Membrane Proteins","Mutation","Neurofibromin 1","Proto-Oncogene Proteins B-raf","Pyridones","Pyrimidinones"],"genes":["BRAF","NRAS","NF1"],"publicationTypes":["Letter","Research Support, Non-U.S. Gov\u0027t"],"title":"BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib.","pubmedId":"25243813"}